The artificial intelligence (AI)-powered Ezra Flash reportedly enhances magnetic resonance imaging (MRI) and enables significant reductions in scan times and costs for full-body MRI.
Could 30-minute full-body magnetic resonance imaging (MRI) exams be a reality in the near future?
The Food and Drug Administration (FDA) has granted 510(k) clearance for Ezra Flash (Ezra), an artificial intelligence-enabled software that enhances the quality of images derived from a fast MRI protocol, according to Ezra, the developer of the software.
Emphasizing that Ezra Flash was trained on hundreds of thousands of MRI scans from a proprietary dataset, Ezra said the technology facilitates simultaneous image quality and scan time reduction to the point where it can reduce the costs of full-body MRI by 30 percent.
Noting that Ezra Flash has received FDA clearance for brain imaging, the company plans to utilize the technology to launch the first 30-minute full-body MRI.
Possibly facilitating proactive cancer detection for a broader patient base beyond those with established risk factors, the FDA clearance of Ezra Flash may represent the “ … beginning of a sea change in how medical imaging is used,” noted Daniel K. Sodickson, M.D., Ph.D., the chief of innovation and director of the Center for Advanced Imaging Innovation and research in the Department of Radiology at New York University (NYU).
“Ezra Flash will increase the accessibility of early-warning MRI, and Ezra’s dataset of repeated scans over time will help it to prevent false positives and ensure that the warnings it provides are appropriate and accurate,” emphasized Dr. Sodickson.
(Editor’s note: For related content, see “Can Alternative MRI Techniques Help Enhance CyberKnife Treatment Imaging?”)
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.